P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data

• Julia Driessen,
• Fer De Wit,
• Alex F. Herrera,
• Pier Luigi Zinzani,
• Ann S. Lacasce,
• Peter D. Cole,
• Craig H. Moskowitz,
• Ramón. García Sanz,
• Michael Fuchs,
• Horst Müller,
• Peter Borchmann,
• Armando Santoro,
• Heiko Schöder,
• Josée. M. Zijlstra,
• Barbara A. Hutten,
• Alison J. Moskowitz,
• Marie José Kersten

Affiliations

Julia Driessen

1 Department of Hematology, Amsterdam UMC, University of Amsterdam, LYMMCARE, Cancer Center Amsterdam, Amsterdam, The Netherlands

Fer De Wit

1 Department of Hematology, Amsterdam UMC, University of Amsterdam, LYMMCARE, Cancer Center Amsterdam, Amsterdam, The Netherlands

Alex F. Herrera

2 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA

Pier Luigi Zinzani

3 Institute of Hematology, University of Bologna, Bologna, Italy

Ann S. Lacasce

4 Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

Peter D. Cole

5 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Craig H. Moskowitz

6 Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, USA

Ramón. García Sanz

7 Department of Hematology, Hospital Universitario de Salamanca, Spain, Salamanca, Spain

Michael Fuchs

8 German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Horst Müller

8 German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Peter Borchmann

8 German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Armando Santoro

9 Department of Biomedical Sciences, Humanitas University, IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Milan, Italy

Heiko Schöder

10 Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Josée. M. Zijlstra

11 Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Netherlands, Amsterdam, The Netherlands

Barbara A. Hutten

12 Department of Epidemiology and Data Science, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Alison J. Moskowitz

13 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Marie José Kersten

1 Department of Hematology, Amsterdam UMC, University of Amsterdam, LYMMCARE, Cancer Center Amsterdam, Amsterdam, The Netherlands